| Literature DB >> 28389709 |
C Fiehn1.
Abstract
Familial chilblain lupus belongs to the group of type 1 interferonopathies and is particularly characterized by typical skin manifestations and ischemia of the acra. There are various mutations that can lead to this autosomal dominant disease. A mutation in the TREX-1 gene has been most frequently found; however, families with mutations in the SAMHD1 gene and recently in the gene which codes for the stimulator of interferon genes (STING) protein were also described. A common feature of these genetic defects is that they are all involved in the process of detection of intracellular free DNA, which as a result leads to increased production of type 1 interferons and the induced gene products. This then leads to autoinflammation and autoimmunity, which is characteristic for the disease. The activation of interferon-induced genes is controlled by the JAK-STAT system; therefore, JAK inhibitors were successfully used in several cases to treat type 1 interferonopathies. Experience with this treatment modality is continuously growing.Entities:
Keywords: Autoimmunity; Autoinflammation; Autosomal dominant; JAK inhibitors; Mutation
Mesh:
Substances:
Year: 2017 PMID: 28389709 DOI: 10.1007/s00393-017-0285-5
Source DB: PubMed Journal: Z Rheumatol ISSN: 0340-1855 Impact factor: 1.372